Key Takeaways Accelerated uptake of key therapies and strategic disease awareness efforts position Zevra for outsized growth, stronger margins, and rapid expansion in both U.S. and European markets. Solid capital resources and first-mover advantages enable Zevra to pursue aggressive pipeline and partnership opportunities without relying on additional financing.Read more
Key Takeaways Reliance on rare disease therapies limits growth due to narrow patient pools, slow diagnoses, and physician awareness, posing risks to stable revenue and earnings expansion. High operating and R&D expenses, coupled with competitive pressures and payer resistance, threaten profit margins and may weaken future financial flexibility.Read more
Key Takeaways Strong market traction and geographic expansion efforts position Zevra for sustained revenue growth and increased earnings visibility in the rare disease therapy segment. Robust financial flexibility enables continued pipeline investment and strategic initiatives without dilutive financing, supporting long-term profitability and scalability.Read more
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
